It specifically impairs the binding functions of TREM2 in vivo through inducing structural changes [23], and this loss-of-function could reduce microglial activation, thereby affecting Aβ clearance in the brain, promoting AD pathogenesis [25]. This evidence concerns the gene TREM2 and Alzheimer disease.